Leading in the News.

Substitution Of Pegylated Liposomal Doxorubicin For Gemcitabine In Standard Platinum-Based Regimen May Improve Survival In Patients With Recurrent Ovarian Cancer. (4/21, Harrison) reports researchers found in a phase 3 trial that “replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer.” Researchers found that “in a cohort of nearly 700 women receiving carboplatin plus bevacizumab (Avastin), median progression-free survival (PFS) was 13.3 months for the group that also received pegylated liposomal doxorubicin, as compared with 11.6 months for those assigned to standard gemcitabine therapy.” The findings were published in The Lancet Oncology.